Report: Johnson & Johnson cuts comprehensive care unit

NEW YORK One of the largest pharmaceutical manufacturers in the United States is eliminating its comprehensive care unit, according to published reports.

The Associated Press reported that Johnson & Johnson would eliminate its comprehensive care unit — the unit that includes businesses making diabetes products, diagnostic tests, contact lenses, catheters and other items. Last year, the unit had $10 billion in revenues, but sales decreased by 8% in the first half of this year, compared with last year.

AP also reported that the company had been forced to reduce costs due to generic competition against drugs like the antipsychotic Risperdal (risperidone) and Topamax (topiramate), used to treat migraine headaches epilepsy, while strengthening of the dollar had harmed sales in other countries.